F16.180
Hallucinogen abuse with hallucinogen-induced anxiety disorder
Clinical Classification Guidelines
Medical Intelligence & Overview
ICD-10 code F16.180 refers to a condition where an individual abuses hallucinogenic substances and develops an accompanying anxiety disorder induced by these substances. Hallucinogens are a class of drugs known for altering perception, mood, and various cognitive processes. Abuse of these substances can lead to significant mental health issues, including anxiety disorders, which further impact an individual's well-being. Recognizing the signs, causes, and implications of this condition is crucial for effective management and support.
Causes & Symptoms
Clinical Causes: Repeated use of hallucinogenic substances such as LSD, psilocybin, or mescaline. Underlying mental health conditions that make individuals more vulnerable to substance abuse. Peer pressure or social environments that promote drug experimentation. Psychological factors such as stress, trauma, or seeking escapism. Genetic predisposition towards substance dependence or mental health disorders.
Key Symptoms: Altered perceptions or hallucinations, especially during substance use. Persistent anxiety or panic attacks, often triggered or worsened by hallucinogen use. Suspiciousness or paranoia. Restlessness or hyperactivity. Sleep disturbances, such as insomnia or nightmares. Feelings of fear, dread, or impending doom. Difficulty concentrating or maintaining focus. Physical symptoms like increased heart rate, sweating, and trembling during episodes.
Diagnostic & Treatment
Diagnosis Path: Diagnosing this condition involves a thorough clinical assessment by a healthcare professional, including a detailed history of substance use and mental health. Laboratory tests may not detect hallucinogens directly but can help rule out other causes of symptoms. Mental health evaluations focus on identifying signs of anxiety and substance abuse patterns. It is essential to differentiate this condition from other mental health disorders with similar symptoms. The diagnosis considers the presence of hallucinogen use coinciding with anxiety symptoms specifically induced by substance intake.
Treatment Protocols: Approaches to managing this condition typically include behavioral therapies such as cognitive-behavioral therapy (CBT) to address both substance abuse and anxiety. Support groups and counseling may also provide essential psychosocial support. In some cases, medications might be prescribed to manage anxiety symptoms, but this must be carefully monitored. The primary goal is to reduce or eliminate hallucinogen use, address anxiety symptoms, and prevent future episodes. Developing coping strategies to handle triggers and underlying issues plays a key role in recovery.
Clinical Advice & FAQs
Billing Guidance
Is F16.180 a billable ICD-10 code?
Yes, F16.180 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report F16.180?
Clinical documentation must specify the nature of Hallucinogen abuse with hallucinogen-induced anxiety disorder and any associated comorbidities for accurate reporting.
Cite this Clinical Reference